[Hiring] Senior Director, Commercial Lead, UK @Revolution Medicines

Role Description

The Senior Director, Commercial Lead, UK is responsible for defining and executing the local commercial strategy for oncology products. This role is accountable for building the commercial organization, driving launch and growth performance, and ensuring strong alignment across Medical Affairs, Market Access, and other key functions.

• Act as the Commercial Lead for UK accountable for local commercial strategy, execution, and performance across the oncology portfolio.
• Serve as a core member of the UK Leadership Team, contributing to strategy, launch planning, and business decisions.
• Partner with regional and local Medical Affairs and Marketing Team to translate clinical and economic evidence into compelling value communications tailored for UK stakeholders including HCPs and payers.
• Translate regional commercial strategy into locally optimized plans aligned with market dynamics, customer needs, and healthcare system requirements.
• Collaborate with regional commercial teams by representing the country and contributing to commercial plans shaping our strategy.
• Develop and execute country-level brand and portfolio strategies across pre-launch, launch, and post-launch phases.
• Drive demand generation and appropriate use through non-promotional and promotional channels in compliance with local regulations.
• Lead forecasting, budgeting, and operational planning for the country in close collaboration with the ED, Commercial Excellence, Business Analytics and Insights, Europe.
• Lead commercial launch readiness for oncology products, including customer strategy, segmentation, targeting, and field force planning.
• Partner closely with Medical Affairs and Market Access to ensure integrated launch execution and consistent external engagement.
• Monitor performance, competitive dynamics, and market trends, adjusting strategy as needed.
• Oversee customer engagement strategy across key stakeholders, including oncologists, treatment centers, and healthcare organizations.
• Ensure effective field force deployment and capability building (e.g., sales, key account management, customer-facing roles).
• Work closely with Medical Affairs, Market Access, Regulatory, Finance, Corporate Affairs and other support functions to ensure aligned and compliant country execution.
• Ensure strong integration of commercial plans with access, medical, and evidence strategies.
• Build, lead, and develop the country commercial organization, including sales, marketing, and customer-facing roles as the business scales.
• Establish commercial processes, governance, and ways of working as part of the country build-out.
• Foster a culture of accountability, collaboration, and performance excellence.
• Contribute to regional and country-specific initiatives.
• Travel nationally and internationally.

Qualifications

• Advanced degree required (e.g., MSc, PhD, MD, PharmD).
• 10+ years of experience in pharmaceutical or biotech commercial roles.
• Significant experience in oncology commercial leadership at country level.
• Proven track record of successful oncology product launches in UK and successful HCP / KOL interactions.
• Proven project management experience.
• Excellent communication skills, both in person and virtual.
• Scientific and solution-oriented mindset and capability to move and execute in a rapidly changing, ambiguous environment.
• Strong understanding of local healthcare systems, customer dynamics, and reimbursement environments.
• Experience in a US-based or global biotech and/or in a build-out or first-in-country role strongly preferred.
• Proven leadership and people management capabilities; demonstrated success in small but fast-growing, entrepreneurial commercial environment.
• High capacity of social competence for teamwork, coaching and situational leadership.

Company Description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.